Integrated In Silico, Lab Assessments For Faster Drug Development

By Andrea Arsiccio, Ph.D., Senior Scientist, Eva Keilhauer, Ph.D., Business Development Manager, and Kristian Le Vay, Ph.D., Expert Scientist

Late‑stage failures remain some of the most costly challenges in drug development, often resulting from advancing molecules that later prove difficult to formulate or manufacture. Integrating in‑silico modeling with laboratory‑based developability assessments provides early insight into molecular liabilities before they become major obstacles. By predicting risks related to stability, aggregation, degradation, viscosity, and overall manufacturability, this combined approach supports smarter molecule selection and more efficient formulation strategies.

As timelines compress and pipelines expand, early scrutiny is increasingly essential. Evaluating biophysical properties—such as stability, formulatability, and compatibility with commercial manufacturing—helps teams avoid progressing candidates likely to fail in expensive later stages. In‑silico tools offer rapid, material‑sparing predictions that guide targeted lab experiments and focus resources on the most promising molecules.

This integrated workflow accelerates decision‑making, reduces costs, streamlines development, and improves the likelihood of advancing biologic therapies from discovery to commercialization through a more efficient, data‑driven strategy.